Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Vedolizumab IV for Steroid-Refractory Acute Intestinal GvHD in Pts who Undergone allo-HSCT

Protocol: OSU-17003

Full Title

An Open-Label, Dose-Finding Study of Vedolizumab IV for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Patients who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)